Aston University teams up with biotechnology company to develop commercial-scale production of membrane-associated proteins

Feb 14, 2022

3 min

Roslyn Bill

Aston University has teamed up with biotechnology company Biocleave Ltd in a new knowledge transfer partnership (KTP) to develop the company’s capacity to produce membrane-associated proteins on a competitive commercial scale.



The partnership will see Aston University’s world-leading expertise provide next-level solutions to a complex problem and provide exciting breakthroughs from both commercial and scientific standpoints.


A knowledge transfer partnership (KTP) is a three-way collaboration between a business, an academic partner and a highly qualified graduate, known as a KTP associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is the leading KTP provider within the Midlands.


Biocleave Ltd produces ‘Research Use Only’ (RUO) proteins. These are used widely in industry and academia to study and develop diagnostics and disease treatments. The process of manufacturing these proteins is known as ‘expression’, requiring host cells to produce them.


The company is the first to engineer the non-pathogenic microbe Clostridia as a recombinant protein expression host, enabling them to overcome the typical expression challenges of production host toxicity and costly development cycles.


Initial trials have demonstrated advantages to making membrane-associated proteins in Clostridia compared with established production systems. However, these proteins are associated with the fatty membrane that surrounds a cell and are not soluble in water.


While Biocleave has well-established proprietary technology for manipulating the microbes, they want to extend their expertise for purifying these challenging membrane proteins, essential to commercialising their production.


The Aston University team will be led by Dr Alan Goddard, senior lecturer in biochemistry in the School of Biosciences and founding member of Aston Membrane Proteins and Lipids (AMPL). Dr Goddard’s research focuses on the application of membrane biology to industrially relevant problems. He has nearly 20 years' experience working with membranes and their integral proteins.


Dr Goddard will be joined by Professor Roslyn Bill, associate dean (research) for the College of Health and Life Sciences and director of AMPL. Professor Bill’s research focuses on the purification and characterisation of membrane proteins and she has published extensively on yeast as a recombinant expression host.


Commenting on the project, Dr Goddard said: “This is a really exciting opportunity to leverage the decades of research experience Professor Bill and I have with expressing and purifying membrane proteins. It will allow Biocleave to enter new markets, many of which are important for drug development and healthcare. Hopefully, the products we make will have positive benefits not only for Biocleave’s customers but also wider society.”


Dr Liz Jenkinson, chief executive of Biocleave Ltd, said: “We’ve made great progress in establishing the technology to work with Clostridia, a promising host, and although we’re constantly learning, so much is still unknown about the clostridial membrane. Through this KTP partnership with Aston University, we’re excited to develop the skills of our staff and expand our commercial offering to extend our range of RUO protein targets.”


Because the Clostridial membrane adds a new level of complexity, successfully developing the required tools internally to resolve these issues, without input from experts, would take considerable time.

Connect with:
Roslyn Bill

Roslyn Bill

Professor of Biotechnology

Professor Bill's research on water flow in the body has revealed how to develop drugs that prevent brain swelling after injury or disease.

Membrane ProteinsBrain SwellingWater BalanceHealthy AgeingBrain Injury

You might also like...

Check out some other posts from Aston University

2 min

Expert comment available - the Government's announcement for the AI Opportunities Action Plan

Expert comment is available on the the Government's announcement for the AI Opportunities Action Plan in which it is aims to roll out AI across the UK. In a speech setting out the government's plans to use AI across the UK to boost growth and deliver services more efficiently, the Prime Minister said the government had a responsibility to make AI "work for working people". The government claims that the AI Opportunities Action Plan is backed by leading tech firms, some of which have committed £14bn towards various projects, creating 13,250 jobs. It includes plans for growth zones where development will be focused, and the technology will be used to help tackle issues such as potholes. Expert comment: "The plan is a necessary step in the right direction with appropriate investment. It should be coupled with a major training programme at business and public levels to bridge the skill gap and develop essential capabilities. "It is important to specify the role that the higher education sector will play in the delivery of such a plan particularly with regards to innovation and knowledge transfer partnerships. "The government used stated that the technology will be used to help tackle issues such as potholes, however AI should be used not only in the detection of potholes, but also in their prediction. Using predictive analytics would significantly reduce the number of cameras that must be deployed to monitor road surface conditions up and down the country." Professor Abdul Hamid Sadka, Professor of Visual Media Technologies, Director, The Sir Peter Rigby Digital Futures Institute, Aston University For further details contact Nicola Jones, Head of Press & Communications (interim) on (+44) 7825 342091 or email: n.jones6@aston.ac.uk

5 min

Aston University and Birmingham Women and Children’s Hospital developing new devices to improve drug treatment safety

The new device is designed to reduce the risk of injuries when medicines being delivered into a vein enter the surrounding tissues It detects this problem at the earliest stages, before it is visible to the human eye The project is being supported by SPARK The Midlands at Aston University, a network to support technology development for unmet clinical needs. Clinicians at Birmingham Women’s and Children's NHS Foundation Trust (BWC) have joined with academics at Aston University to create an innovative sensor to reduce the risk of injuries caused when drugs being delivered into a vein enter the surrounding tissue. This complication, called extravasation, can cause harm and, in the most severe cases, life-changing injuries and permanent scarring. It happens most often when infusing medicines into peripheral intravenous (IV) devices, such as a cannula, but can also occur when infusing into a central venous access device. By joining together, BWC and Aston University are combining clinical, academic and engineering expertise to create a sensor that can detect extravasation at its earliest stages. Karl Emms, lead nurse for patient safety at BWC, said: “We've done lots of work across our Trust that has successfully reduced incidents. While we've made fantastic progress, there is only so much we can do as early signs of extravasation can be difficult to detect with the human eye. “The next step is to develop a technology that can do what people can't - detection as it happens. This will make a huge impact on outcomes as the faster we can detect extravasation, the less likely it is that it will cause serious harm.” The focused work to date addressing the issue has recently been recognised by the Nursing Times Awards 2024, winning the Patient Safety Improvement title for this year. This new project is supported by SPARK The Midlands, a network at Aston University dedicated to providing academic support to advance healthcare research discoveries in the region. SPARK The Midlands is the first UK branch of Stanford University's prestigious global SPARK programme. It comes as a result of Aston University’s active involvement in the delivery of the West Midlands Health Tech Innovation Accelerator (WMHTIA) – a government-funded project aimed at helping companies drive their innovations towards market success. The SPARK scheme helps to provide mentorship and forge networks between researchers, those with technical and specialist knowledge and potential sources of funding. SPARK members have access to workshops led by industry experts, covering topics such as medical device regulations, establishing good clinical trials, and creating an enticing target product profile to engage future funders. Luke Southan, head of research commercialisation at Aston University and SPARK UK director, said: “I was blown away when Karl first brought this idea to me. I knew we had to do everything we could to make this a reality. This project has the potential to transform the standard of care for a genuine clinical need, which is what SPARK is all about.” Work on another potentially transformative project has also begun as the team are working to develop a medical device that detects the position of a nasogastric feeding tube. There is a risk of serious harm and danger to life if nasogastric tubes move into the lungs, rather than the stomach, and feed is passed through them. Emms explained: “pH test strips can usually detect nasogastric tube misplacement, but some children undergoing treatment can have altered pH levels in the stomach. This means this test sometimes does not work. “A medical device that can detect misplacement can potentially stop harm and fatalities caused by these incidents.” SPARK will bring together engineers, academics and clinicians for both projects to develop the devices for clinical trial, with a goal of the technologies being ready for clinical use in three to five years. Southan said: “BWC is one of our first partners at SPARK and we're really excited to work with them to make a vital impact on paediatric healthcare in the Midlands and beyond." Notes to editors About Aston University For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally. Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world. Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming the Guardian University of the Year in 2020. Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world. For media inquiries in relation to this release, contact Helen Tunnicliffe, Press and Communications Manager, on (+44) 7827 090240 or email: h.tunnicliffe@aston.ac.uk About Birmingham Women’s and Children’s NHS Foundation Trust Birmingham Women’s and Children’s NHS Foundation Trust (BWC) brings together the very best in paediatric and women’s care in the region and is proud to have many UK and world-leading surgeons, doctors, nurses, midwives and other allied healthcare professionals on its team. Birmingham Children’s Hospital is the UK’s leading specialist paediatric centre, caring for sick children and young people between 0 and 16 years of age. Based in the heart of Birmingham city centre, the hospital is a world leader in some of the most advanced treatments, complex surgical procedures and cutting-edge research and development. It is a nationally designated specialist centre for epilepsy surgery and also boasts a paediatric major trauma centre for the West Midlands, a national liver and small bowel transplant centre and a centre of excellence for complex heart conditions, the treatment of burns, cancer and liver and kidney disease. The hospital is also home to one of the largest Child and Adolescent Mental Health Services in the country, comprising of a dedicated inpatient Eating Disorder Unit and Acute Assessment Unit for regional referrals of children and young people with the most serious of problems (Tier 4) and Forward Thinking Birmingham community mental health service for 0- to 25-year-olds. Birmingham Women’s Hospital is a centre of excellence, providing a range of specialist health care services to over 50,000 women and their families every year from Birmingham, the West Midlands and beyond. As well as delivering more than 8,200 babies a year, it offers a full range of gynaecological, maternity and neonatal care, as well as a comprehensive genetics service, which serves men and women. Its Fertility Centre is one of the best in the country, while the fetal medicine centre receives regional and national referrals. The hospital is also an international centre for education, research and development with a research budget of over £3 million per year. It also hosts the national miscarriage research centre – the first of its kind in the UK - in partnership with Tommy’s baby charity. For interview requests please email the Communications Team on bwc.communications@nhs.net

3 min

Aston University researcher develops new optical technique that could revolutionise medical diagnostics

New light technique could revolutionise non-invasive medical diagnostics Orbital Angular Momentum could be harnessed to improve imaging and data transmission through biological tissues Could eventually have potential to make procedures such as surgery or biopsies unnecessary. An Aston University researcher has developed a new technique using light which could revolutionise non-invasive medical diagnostics and optical communication. The research showcases how a type of light called the Orbital Angular Momentum (OAM) can be harnessed to improve imaging and data transmission through skin and other biological tissues. A team led by Professor Igor Meglinski found that OAM light has unmatched sensitivity and accuracy that could result in making procedures such as surgery or biopsies unnecessary. In addition it could enable doctors to track the progression of diseases and plan appropriate treatment options. OAM is defined as a type of structured light beams, which are light fields which have a tailored spatial structure. Often referred to as vortex beams, they have previously been applied to a number of developments in different applications including astronomy, microscopy, imaging, metrology, sensing, and optical communications. Professor Meglinski in collaboration with researchers from the University of Oulu, Finland conducted the research which is detailed in the paper “Phase preservation of orbital angular momentum of light in multiple scattering environment” which is published in the Nature journal Light Science & Application. The paper has since been named as one of the year’s most exciting pieces of research by international optics and photonics membership organisation, Optica. The study reveals that OAM retains its phase characteristics even when passing through highly scattering media, unlike regular light signals. This means it can detect extremely small changes with an accuracy of up to 0.000001 on the refractive index, far surpassing the capabilities of many current diagnostic technologies. Professor Meglinski who is based at Aston Institute of Photonic Technologies said: “By showing that OAM light can travel through turbid or cloudy and scattering media, the study opens up new possibilities for advanced biomedical applications. “For example, this technology could lead to more accurate and non-invasive ways to monitor blood glucose levels, providing an easier and less painful method for people with diabetes.” The research team conducted a series of controlled experiments, transmitting OAM beams through media with varying levels of turbidity and refractive indices. They used advanced detection techniques, including interferometry and digital holography, to capture and analyse the light's behaviour. They found that the consistency between experimental results and theoretical models highlighted the ability of the OAM-based approach. The researchers believe that their study’s findings pave the way for a range of transformative applications. By adjusting the initial phase of OAM light, they believe that revolutionary advancements in fields such as secure optical communication systems and advanced biomedical imaging will be possible in the future. Professor Meglinski added: "The potential for precise, non-invasive transcutaneous glucose monitoring represents a significant leap forward in medical diagnostics. “My team’s methodological framework and experimental validations provide a comprehensive understanding of how OAM light interacts with complex scattering environments, reinforcing its potential as a versatile technology for future optical sensing and imaging challenges.” ENDS https://www.nature.com/articles/s41377-024-01562-7 Light: Science & Applications volume 13, Article number: 214 (2024) August 2024 https://doi.org/10.1038/s41377-024-01562-7 Authors: Igor Meglinski, Ivan Lopushenko, Anton Sdobnov & Alexander Bykov About Aston University For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally. Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world. Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming The Guardian University of the Year in 2020. Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world. For media inquiries in relation to this release, contact Nicola Jones, Press and Communications Manager, on (+44) 7825 342091 or email: n.jones6@aston.ac.uk

View all posts